Clinical Guidelines

The Test That Could Save Patients' Bladders

Blood and urine tumor DNA monitoring may identify patients who can safely avoid cystectomy

  • By

  • February 26, 2026

  • 2 min

Share

Recent research highlights the potential of monitoring circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) to identify patients with muscle-invasive bladder cancer who may avoid radical cystectomy after treatment. In a clinical trial, a notable 69% of patients with a complete clinical response maintained bladder integrity after three years. The study, led by Matthew Galsky, reveals that while detectable ctDNA signals a higher risk of metastatic disease, utDNA's sensitivity to residual disease provides critical insights. This dual testing could reshape treatment strategies for bladder cancer management.

Original Source(s)

The Test That Could Save Patients' Bladders

Blood and urine tumor DNA monitoring may identify patients who can safely avoid cystectomy

  • February 26, 2026

  • 2 min

Related Content

Insights on Sarcomas, Gastroesophageal Cancers, Peritoneal Tumors Anchor Roswell Park Presentations at SSO 2026

A Roswell Park study is shedding light on the little-understood dynamics of the tumor microenvironment (TME) in two types of rare and aggressive sarcomas — dedifferentiated liposarcomas (DDLPS) and leiomyosarcomas (LMS). 

  • by

  • February 25, 2026

  • 5 min
Syngene and Johns Hopkins Partner to Advance Early-Stage Drug Discovery

Collaboration anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

  • February 25, 2026

  • 2 min
What Cats Can Tell Us About Cancer

Large-scale feline sequencing study highlights diagnostic and therapeutic targets shared with human cancers

  • February 25, 2026

  • 2 min